MA41555A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA41555A
MA41555A MA041555A MA41555A MA41555A MA 41555 A MA41555 A MA 41555A MA 041555 A MA041555 A MA 041555A MA 41555 A MA41555 A MA 41555A MA 41555 A MA41555 A MA 41555A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer treatment
cancer
treatment
Prior art date
Application number
MA041555A
Other languages
English (en)
Inventor
Andrew Fergus
Richard Labotka
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA41555A publication Critical patent/MA41555A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041555A 2015-02-17 2016-02-15 Polythérapie pour le traitement du cancer MA41555A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117283P 2015-02-17 2015-02-17

Publications (1)

Publication Number Publication Date
MA41555A true MA41555A (fr) 2017-12-26

Family

ID=56689146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041555A MA41555A (fr) 2015-02-17 2016-02-15 Polythérapie pour le traitement du cancer

Country Status (8)

Country Link
US (5) US20180235986A1 (fr)
EP (1) EP3258965A4 (fr)
JP (3) JP2018506550A (fr)
CN (1) CN107249635A (fr)
CA (1) CA2976696A1 (fr)
EA (1) EA201791736A1 (fr)
MA (1) MA41555A (fr)
WO (1) WO2016133903A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
IL319936A (en) 2015-05-20 2025-05-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP4516319A3 (fr) 2015-11-03 2025-05-07 Janssen Biotech, Inc. Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
EP3544612A4 (fr) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. Combinaisons pharmaceutiques comprenant un inhibiteur d'histone désacétylase et un inhibiteur de cd38 et leurs méthodes d'utilisation
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
CA3088199A1 (fr) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Dosage sous-cutane d'anticorps anti-cd38
CN110903310B (zh) 2018-09-14 2022-11-22 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
BR112021007227A2 (pt) * 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
TWI870415B (zh) 2019-06-10 2025-01-21 日商武田藥品工業股份有限公司 使用抗cd38抗體之組合療法
JP7428601B2 (ja) * 2020-06-29 2024-02-06 株式会社神戸製鋼所 ガスシールドアーク溶接方法、構造物の製造方法及びシールドガス
EP4080515A1 (fr) 2021-04-19 2022-10-26 Roche Diagnostics GmbH Procédé de classification d'une étiquette d'identification sur un tube d'échantillon contenant un échantillon et système de laboratoire automatisé

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912554TA (en) * 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CN102961387B (zh) * 2007-08-06 2016-04-27 米伦纽姆医药公司 蛋白酶体抑制剂
CN101772507B (zh) * 2007-08-06 2012-12-12 米伦纽姆医药公司 蛋白酶体抑制剂
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
EP2730580A1 (fr) * 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Composés de borates esters et compositions pharmaceutiques contenant des composés
BR112013006769B1 (pt) * 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3769783A1 (fr) * 2013-03-13 2021-01-27 Sanofi Compositions comprenant des anticorps anti-cd38 et carfilzomib
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
EP3258965A4 (fr) 2018-08-29
CA2976696A1 (fr) 2016-08-25
US20180235986A1 (en) 2018-08-23
US20230201227A1 (en) 2023-06-29
EA201791736A1 (ru) 2017-12-29
WO2016133903A3 (fr) 2017-01-05
EP3258965A2 (fr) 2017-12-27
JP2023130496A (ja) 2023-09-20
JP2018506550A (ja) 2018-03-08
CN107249635A (zh) 2017-10-13
WO2016133903A2 (fr) 2016-08-25
US20210369748A1 (en) 2021-12-02
JP2021059564A (ja) 2021-04-15
US20210137955A1 (en) 2021-05-13
US20220184103A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3322448A4 (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
EP3377068A4 (fr) Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA41858A (fr) Polythérapie fgfr/pd-1 destinée au traitement du cancer
EP3488001A4 (fr) Traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA41123A (fr) Polythérapie pour le traitement du cancer
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
MA47408A (fr) Traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3375108A4 (fr) Traitement dewlan
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome